RFS was defined as the time between the date of randomization and the date of first recurrence (local, regional or distant metastasis), new primary melanoma (including melanoma in situ), or death (from any cause), whichever occurred first.

Median values based on Kaplan-Meier Estimates.

All randomized participants with completely resected stage IIIb/c/d or stage IV no evidence of disease (NED) melanoma

RFS was defined as the time between the date of randomization and the date of first recurrence (local, regional or distant metastasis), new primary melanoma (including melanoma in situ), or death (from any cause), whichever occurred first.

Median based on Kaplan-Meier Estimates.

All randomized participants with PD-L1 expression level < 1% and with completely resected stage IIIb/c/d or stage IV no evidence of disease (NED) melanoma. PD-L1 expression levels based on Interactive Response Technology (IRT)

OS is defined as the time between the date of randomization and the date of death. Median based on Kaplan-Meier Estimates.

All randomized participants with completely resected stage IIIb/c/d or stage IV no evidence of disease (NED) melanoma

OS is defined as the time between the date of randomization and the date of death. Median based on Kaplan-Meier Estimates.

All randomized participants with PD-L1 expression level < 1% and with completely resected stage IIIb/c/d or stage IV no evidence of disease (NED) melanoma

RFS was defined as the time between the date of randomization and the date of first recurrence (local, regional or distant metastasis), new primary melanoma (including melanoma in situ), or death (from any cause), whichever occurred first.

Median based on Kaplan-Meier Estimates.

All randomized participants with variable PD-L1 expression levels (see data table for details). PD-L1 expression levels based on clinical database.

Time to next therapy was defined as the time from the date of randomization to the start date of next systemic therapy. Participants who did not receive next treatment were censored at the last known alive date.

Time to second next therapy was defined as the time from the date of randomization to the start date of second next systemic therapy. Participants who did not receive second next treatment were censored at the last known alive date.

All randomized participants

Time to next therapy was defined as the time from the date of randomization to the start date of next systemic therapy. Participants who did not receive next treatment were censored at the last known alive date.

Time to second next therapy was defined as the time from the date of randomization to the start date of second next systemic therapy. Participants who did not receive second next treatment were censored at the last known alive date

All randomized participants with PD-L1 expression level < 1%

Time from next treatment to second next treatment was defined as the time from the start date of next systemic therapy to start date of second next systemic therapy. No censoring rules were applied here as analysis was only performed for the subset of participants who received second next treatment.

All randomized participants who received first and second next systemic therapy

Time from next treatment to second next treatment was defined as the time from the start date of next systemic therapy to start date of second next systemic therapy. No censoring rules were applied here as analysis was only performed for the subset of participants who received second next treatment.

All randomized participants with PD-L1 expression level < 1% who received first and second next therapy

PFS2 was defined as the time from randomization to the progression date on next-line systemic therapy or the end date of next-line systemic therapy (if progression date not available) or death from any cause (if both progression date and end date not available), and to last known alive date in case of no event (ie, censoring), meaning either (1) no subsequent systemic therapy and no death OR (2) subsequent systemic therapy but no progression date nor end date available and no death.

All randomized participants

PFS2 was defined as the time from randomization to the progression date on next-line systemic therapy or the end date of next-line systemic therapy (if progression date not available) or death from any cause (if both progression date and end date not available), and to last known alive date in case of no event (ie, censoring), meaning either (1) no subsequent systemic therapy and no death OR (2) subsequent systemic therapy but no progression date nor end date available and no death.

All randomized participants with PD-L1 expression level < 1%.